• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

CIDRAP- NEWS BRIEF May 22, 2024

Lance

MPH, CSP & CIT Retired, CHMM Emeritus
https://www.cidrap.umn.edu/all-news

Surveillance study describes incidence of multidrug-resistant infections in US children



News brief

Today at 3:19 p.m.
Chris Dall, MA
Topics

Antimicrobial Stewardship

A surveillance study found that carbapenem-resistant Enterobacterales (CRE) infections occur less frequently than extended-spectrum beta-lactamase–producing Enterobacterales (ESBL-E) infections in US children, researchers reported today in Emerging Infectious Diseases.

Led by researchers with the Centers for Disease Control and Prevention's Emerging Infections Program (EIP), the surveillance study analyzed CRE incidence in children in 10 states from 2016 through 2020 and ESBL-E incidence in children in six states from 2019 through 2020. While most US studies have focused on the prevalence and epidemiology of these multidrug-resistant pathogens in adults, nationwide data on children are lacking.

From 2016 through 2020, a total of 159 incident CRE cases were identified in 142 children (median age, 5 years). Most CRE isolates were from urine (82.4%), and the most commonly reported infection type was lower urinary tract infection (UTI, 56.3%). The overall annual CRE incidence rate across the 10 EIP sites was 0.70 cases per 100,000 children.

From 2019 through 2020, 207 incident ESBL-E cases were identified in 184 children, with 94.7% of isolates found in urine and UTIs accounting for 74% of cases. The overall annual ESBL-E incidence rate was 23.08. CRE and ESBL-E incidence rates were more than two-fold higher in infants than in other age-groups and were nearly always higher for girls than boys, except in the youngest age-group.

Rise in community-associated infections


Most CRE and ESBL-E cases were healthcare-associated community-onset (43.0% for CRE vs 23.7% for ESBL-E) or community-associated (27.2% for CRE vs 64.5% for ESBL-E). A greater proportion of children with CRE than ESBL-E underwent acute care hospitalization (46.8% vs 22.5%) or surgery (38.6% vs 9.5%) within 1 year before specimen collection, while ESBL-E cases were significantly more likely than CRE cases to have no reported healthcare exposures (65.1% vs 27.2%).

The study authors say the increasing prevalence of community-associated ESBL-E UTIs mirrors trends observed in adult patients and highlights the need to monitor pediatric populations for these pathogens.

"Continued implementation of national programs to detect, prevent, and treat multidrug-resistant infections must increasingly include pediatric populations and outpatient settings," they wrote.
 
Back
Top Bottom